Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Vilon

KE, L-Lys-L-Glu, lysylglutamic acid

Quick Stats
Studies 40
Trials 100
Completed PHASE1 INTERVENTIONAL NCT03798197

Effect of Food on the Bioavailability of 30 mg Estetrol (E4) Tablet in Healthy Postmenopausal Female Volunteers

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

Assessment of the effect of a high fat meal on the quantity in blood of a female sex hormone called estetrol (E4). The study also aims at determining how subject tolerate the study drug and how safe it is for them.

Interventions

Name: 30 mg estetrol (E4)
Type: DRUG
Description: All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or at the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (sequence AB), or Treatment B followed by Treatment A (sequence BA).

Primary Outcomes

Measure: Maximum concentration (Cmax) of Estetrol in plasma
TimeFrame: Predose, 10, 20, 30, 45 min, 1, 1.25, 1.5, 1.75, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-dose
Description: PK sampling
Measure: Area under the curve (AUC) from time zero to the last determinable concentration of Estetrol
TimeFrame: Predose, 10, 20, 30, 45 min, 1, 1.25, 1.5, 1.75, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-dose
Description: PK sampling
Measure: AUC0-inf of Estetrol
TimeFrame: Predose, 10, 20, 30, 45 min, 1, 1.25, 1.5, 1.75, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-dose
Description: PK sampling

Trial Information

NCT ID

NCT03798197

Status

Completed

Study Type

INTERVENTIONAL

Phases

PHASE1

Sponsor

Donesta Bioscience

Last Updated

December 15, 2025